Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while responding positively to the announcement that Julie Kim will take the helm of the Japanese giant in 2026.
Takeda Drops Epilepsy Drug, Names New CEO Amid Q3 Earnings Read More »
CAR T–focused biotech Cargo Therapeutics surprised and disappointed analysts when it announced that it would discontinue a mid-stage trial of its lead program, firi-cel.
Cargo Halts CAR T Trial, Lays Off 50% of Workforce in Pipeline Reset Read More »
Over half of U.S. states currently have laws banning or reducing access to gender-affirming care like puberty blockers for minors. Under the new directive, even more providers could stop offering treatments.
Trump seeks to ban federal funding for youth gender-affirming care Read More »
Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.
Sanofi Earnings Driven by Dupixent, New RSV Vaccine as Hunt for Deals Continues Read More »
CEO Mattias Perjos said surgical perfusion has “been a struggling category” since an FDA consent decree forced Getinge off the U.S. market in 2015.
Getinge exits surgical perfusion, creating opportunity for Livanova Read More »
For 2025, Roche will continue a careful approach to high-priced deals, putting science at the center of its business development decisions, executives said Thursday.
The genetic testing company ended last year with $79.4 million and told investors it will need to raise money to fund its operations and financial commitments.
While the Chicago metropolitan area is not a major life sciences hub, a recent Cushman & Wakefield report predicts the Chicago market should be a growth spot in the coming years. Chicago Biomedical Consortium and COUR Pharmaceuticals executives share what makes the area a hot spot.
Chicago Area’s Life Sciences Scene Continues Making an Impression Read More »
If approved, suzetrigine would represent the first new drug class for acute pain in more than 20 years.
Vertex Awaits FDA Verdict on Landmark Non-Opioid Pain Drug Read More »
In this episode, presented by the Genscript Biotech Global Forum 2025, BioSpace’s Head of Insights Lori Ellis talks to Tom Whitehead, co-founder of the Emily Whitehead Foundation, about how standard care, cell and gene therapies and their impact on patients.
